A New Approach to Cancer

Addressing resistance, extending duration of response, and increasing progression-free survival

A new option for cancer indications
with significant medical need

We are developing onvansertib, an oral and highly-selective inhibitor of polo-like kinase 1 (PLK1 ), as a new option for cancer indications with significant medical need.

Addressing Resistance

PLK1 is overexpressed in many cancers where it facilitates cell division, promotes biosynthesis of DNA, and enhances the emergence of mutated cancer cells by reducing the cellular response to damaged DNA. Our goal in combining a PLK1 inhibitor with standard-of-care therapy is to stop the development of drug-resistant cells by directly targeting the processes that lead to the emergence of drug resistance.

Our Clinical Programs

Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 2 open-label trial (NCT03414034)

Adding onvansertib to daily Zytiga® to overcome Zytiga® resistance and increase progression-free survival.

Metastatic Colorectal Cancer (mCRC) with a KRAS mutation
Phase 1b/2a open-label trial (NCT03829410)

Combining onvansertib with standard-of-care FOLFIRI/bevacizumab to improve efficacy and increase progression-free survival.

Acute Myeloid Leukemia (AML)
Phase 1b/2 open-label trial (NCT03303339)

Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase progression-free survival.